Showing 2621-2630 of 9131 results for "".
New Drugs and Therapies in 2025: Dr. Bhatia
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/new-drugs-and-therapies-in-2025-dr-bhatia/32688/Neal Bhatia, MD, discusses the drugs, devices, and more that he and Ted Rosen, MD, presented during "New Drugs and Therapies in 2025" at Maui Derm 2025.Urticaria: Dr. Hawkes
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/urticaria-dr-hawkes/32690/Jason Hawkes, MD, talks about how to manage and approach chronic spontaneous urticaria patients, as well as novel therapeutic options, all of which he covered in "Urticaria Update 2025" at Maui Derm 2025.Laser and Energy Devices Session: Dr. Ross
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/laser-and-energy-devices-session-dr-ross/32682/E. Vic Ross, MD, discusses some of the basics and applications that he covered during "Lasers and Energy Devices Used to Treat Medical Problems: What's New in 2025" at Maui Derm 2025.Skin of Color Session: Dr. Taylor
https://practicaldermatology.com/programs/practical-dermatology/skin-of-color-session-dr-taylor/32674/Susan Taylor, MD, summarizes her presentation during the "Skin of Color Session" at Maui Derm 2025, including a discussion of photoprotection for patients with vitiligo, hyperpigmentation, and melasma.Psoriasis Update 2025: Dr. Gelfand
https://practicaldermatology.com/programs/practical-dermatology/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.Pearls for Treating Atopic Skin
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-for-treating-atopic-skin/29483/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with dermatologist James Del Rosso, DO, about different ways to treat patients with atopic dermatitis (AD), including using a well-made moisturizers, and also exploring both the science and the use of newer topical agents. ThisDr. Ross on Therapeutic and Warning Endpoints for Laser Therapy in Skin of Color Patients
https://practicaldermatology.com/topics/skin-of-color/dr-ross-on-therapeutic-and-warning-endpoints-for-laser-therapy-in-skin-of-color-patients/28657/E. Victor Ross, MD, discusses his presentations at the Skin of Color Update, where he addressed ways to enhance using laser therapy in practice on patients with skin of color.SCALE 2024: Dr. Linda Stein Gold on What’s New and What’s Coming in AD
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-linda-stein-gold-on-whats-new-and-whats-coming-in-ad/26412/Linda Stein Gold, MD, discusses new topical, oral, and biologic drugs for the treatment of atopic dermatitis at Music City SCALE.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.